{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:30Z","timestamp":1789434510794,"version":"build-2803163510"},"reference-count":256,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/TSG\/20\/1\/600029"],"award-info":[{"award-number":["IA\/TSG\/20\/1\/600029"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Successful sequencing of the human genome and evolving functional knowledge of gene products has taken genomic medicine to the forefront, soon combining broadly with traditional diagnostics, therapeutics, and prognostics in patients. Recent years have witnessed an extraordinary leap in our understanding of ocular diseases and their respective genetic underpinnings. As we are entering the age of genomic medicine, rapid advances in genome sequencing, gene delivery, genome surgery, and computational genomics enable an ever-increasing capacity to provide a precise and robust diagnosis of diseases and the development of targeted treatment strategies. Inherited retinal diseases are a major source of blindness around the world where a large number of causative genes have been identified, paving the way for personalized diagnostics in the clinic. Developments in functional genetics and gene transfer techniques has also led to the first FDA approval of gene therapy for LCA, a childhood blindness. Many such retinal diseases are the focus of various clinical trials, making clinical diagnoses of retinal diseases, their underlying genetics and the studies of natural history important. Here, we review methodologies for identifying new genes and variants associated with various ocular disorders and the complexities associated with them. Thereafter we discuss briefly, various retinal diseases and the application of genomic technologies in their diagnosis. We also discuss the strategies, challenges, and potential of gene therapy for the treatment of inherited and acquired retinal diseases. Additionally, we discuss the translational aspects of gene therapy, the important vector types and considerations for human trials that may help advance personalized therapeutics in ophthalmology. Retinal disease research has led the application of precision diagnostics and precision therapies; therefore, this review provides a general understanding of the current status of precision medicine in ophthalmology.<\/jats:p>","DOI":"10.3389\/fmed.2022.906482","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T04:42:27Z","timestamp":1657860147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies"],"prefix":"10.3389","volume":"9","author":[{"given":"Priyalakshmi","family":"Panikker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomereeta","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuprita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Poornachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkasubhra","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3978\/J.ISSN.2224-4336.2015.04.03","article-title":"Retinal dystrophies, genomic applications in diagnosis and prospects for therapy.","volume":"4","author":"Nash","year":"2015","journal-title":"Transl Pediatr."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2021.794805\/BIBTEX","article-title":"Gene-based therapeutics for inherited retinal diseases.","volume":"12","author":"Fenner","year":"2022","journal-title":"Front Genet."},{"key":"B3","year":"2022","journal-title":"Summaries."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-021-00180-1","article-title":"Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan.","volume":"6","author":"Chen","year":"2021","journal-title":"NPJ Genomic Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/GENES10090654","article-title":"Molecular therapies for inherited retinal diseases\u2014current standing.","volume":"10","author":"V\u00e1zquez-Dom\u00ednguez","year":"2019","journal-title":"Opportunit Challeng Genes (Basel)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14712598.2018.1389886","article-title":"Gene therapy for inherited retinal and optic nerve degenerations.","volume":"18","author":"Moore","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/S11095-019-2569-8","article-title":"Review of biomarkers in ocular matrices: challenges and opportunities.","volume":"36","author":"Tamhane","year":"2019","journal-title":"Pharm Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature.","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege.","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/S00005-009-0030-0","article-title":"Role of ocular pigment epithelial cells in immune privilege.","volume":"57","author":"Sugita","year":"2009","journal-title":"Arch Immunol Ther Exp."},{"key":"B11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/J.PRETEYERES.2008.09.003","article-title":"Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management.","volume":"27","author":"Kaur","year":"2008","journal-title":"Prog Retin Eye Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/MT.2009.277","article-title":"Gene therapy for Leber\u2019s congenital amaurosis is safe and effective through 1.5 years after vector administration.","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1046-2023(02)00232-3","article-title":"Gene delivery to the eye using adeno-associated viral vectors.","volume":"28","author":"Martin","year":"2002","journal-title":"Methods."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.4103\/IJO.IJO_3117_20","article-title":"Gene therapy in retinal diseases: a review.","volume":"69","author":"Dhurandhar","year":"2021","journal-title":"Indian J Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations.","volume":"86","author":"Botto","year":"2022","journal-title":"Prog Retin Eye Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2020.00838\/BIBTEX","article-title":"Novel therapeutic approaches for the treatment of retinal degenerative diseases: focus on CRISPR\/Cas-based gene editing.","volume":"14","author":"Gallego","year":"2020","journal-title":"Front Neurosci."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOCO.2018.01.006","article-title":"Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation.","volume":"30","author":"Ameri","year":"2018","journal-title":"J Curr Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2021.750586","article-title":"Gene therapy in inherited retinal diseases: an update on current state of the art.","volume":"8","author":"Amato","year":"2021","journal-title":"Front Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1167\/IOVS.15-18167","article-title":"Omics in ophthalmology: advances in genomics and precision medicine for Leber congenital amaurosis and age-related macular degeneration.","volume":"57","author":"den Hollander","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18240\/IJO.2018.01.20","article-title":"Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders.","volume":"11","author":"Singh","year":"2018","journal-title":"Int J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-GENOM-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together.","volume":"15","author":"Fritsche","year":"2014","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"B22","year":"2022","journal-title":"Genes, Behavior, and the Social Environment - NCBI Bookshelf."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22115684","article-title":"Next-Generation sequencing applications for inherited retinal diseases.","volume":"22","author":"Dockery","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/AOS.14479","article-title":"Comprehensive genomic diagnosis of inherited retinal and optical nerve disorders reveals hidden syndromes and personalized therapeutic options.","volume":"98","author":"Di\u00f1eiro","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/13816810.2018.1533027","article-title":"Gene therapy for RPE65-related retinal disease.","volume":"39","author":"Miraldi Utz","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"B26","author":"Moosajee","year":"2018","journal-title":"PAX6-Related Aniridia. GeneReviews\u00a7"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.YGENO.2015.11.003","article-title":"The sequence of sequencers: The history of sequencing DNA.","volume":"107","author":"Heather","year":"2016","journal-title":"Genomics."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/CPMB.59","article-title":"Overview of next generation sequencing technologies.","volume":"122","author":"Slatko","year":"2018","journal-title":"Curr Protoc Mol Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/NRG3306","article-title":"ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions.","volume":"13","author":"Furey","year":"2012","journal-title":"Nat Rev Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ophtha.2018.12.050","article-title":"The Oculome panel test: next-generation sequencing to diagnose a diverse range of genetic developmental eye disorders.","volume":"126","author":"Patel","year":"2018","journal-title":"Ophthalmology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/S41431-019-0548-5","article-title":"Diagnostic yield of panel-based genetic testing in syndromic inherited retinal disease.","volume":"28","author":"Jiman","year":"2020","journal-title":"Eur J Hum Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/GIM.2014.172","article-title":"Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing.","volume":"17","author":"Consugar","year":"2015","journal-title":"Genet Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/MGG3.1663","article-title":"Panel-based genetic testing for inherited retinal disease screening 176 genes.","volume":"9","author":"Sheck","year":"2021","journal-title":"Mol Genet genomic Med."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-77558-1","article-title":"EYS is a major gene involved in retinitis pigmentosa in Japan: genetic landscapes revealed by stepwise genetic screening.","volume":"10","author":"Numa","year":"2020","journal-title":"Sci Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/S41436-018-0345-5","article-title":"Biallelic sequence and structural variants in RAX2 are a novel cause for autosomal recessive inherited retinal disease.","volume":"21","author":"Van de Sompele","year":"2019","journal-title":"Genet Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/J.OPHTHA.2012.06.033","article-title":"Identification of an RP1 prevalent founder mutation and related phenotype in Spanish patients with early-onset autosomal recessive retinitis.","volume":"119","author":"Avila-Fernandez","year":"2012","journal-title":"Ophthalmology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81093-y","article-title":"Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications.","volume":"11","author":"Perea-Romero","year":"2021","journal-title":"Sci Reports."},{"key":"B38","article-title":"A novel intronic mutation of PDE6B is a major cause of autosomal recessive retinitis pigmentosa among Caucasus Jews.","volume":"25","author":"Tatour","year":"2019","journal-title":"Mol Vis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/jhg.2013.114","article-title":"The promise of whole-exome sequencing in medical genetics.","volume":"59","author":"Rabbani","year":"2013","journal-title":"J Hum Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/J.PRETEYERES.2017.03.003","article-title":"Unravelling the genetics of inherited retinal dystrophies: past, present and future.","volume":"59","author":"Broadgate","year":"2017","journal-title":"Prog Retin Eye Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/CGE.13171","article-title":"A novel nonsense variant in REEP6 is involved in a sporadic rod-cone dystrophy case.","volume":"93","author":"M\u00e9j\u00e9case","year":"2018","journal-title":"Clin Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/J.AJHG.2016.10.008","article-title":"Mutations in REEP6 cause autosomal-recessive retinitis pigmentosa.","volume":"99","author":"Arno","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1167\/iovs.15-17976","article-title":"Nonsyndromic retinal dystrophy due to bi-allelic mutations in the ciliary transport gene IFT140.","volume":"57","author":"Hull","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/nejmra1711801","article-title":"Next-generation sequencing to diagnose suspected genetic disorders.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/HUMU.22813","article-title":"Comparison of exome and genome sequencing technologies for the complete capture of protein-coding regions.","volume":"36","author":"Lelieveld","year":"2015","journal-title":"Hum Mutat."},{"key":"B46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/S00439-015-1631-9","article-title":"Clinical sequencing: is WGS the better WES?","volume":"135","author":"Meienberg","year":"2016","journal-title":"Hum Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/NATURE07517","article-title":"Accurate whole human genome sequencing using reversible terminator chemistry.","volume":"456","author":"Bentley","year":"2008","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/NMETH.1311","article-title":"Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes.","volume":"6","author":"Kozarewa","year":"2009","journal-title":"Nat Methods."},{"key":"B49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/GIM.2017.119","article-title":"Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.","volume":"20","author":"Lionel","year":"2018","journal-title":"Genet Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/GIM.2016.119","article-title":"arrEYE: a customized platform for high-resolution copy number analysis of coding and noncoding regions of known and candidate retinal dystrophy genes and retinal noncoding RNAs.","volume":"19","author":"Van Cauwenbergh","year":"2017","journal-title":"Genet Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.AJHG.2016.12.003","article-title":"Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease.","volume":"100","author":"Carss","year":"2017","journal-title":"Am J Hum Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/NRG1692","article-title":"The new cytogenetics: blurring the boundaries with molecular biology.","volume":"6","author":"Speicher","year":"2005","journal-title":"Nat Rev Genet."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-249","article-title":"Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma.","volume":"6","author":"Tanimoto","year":"2006","journal-title":"BMC Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1167\/IOVS.11-9027","article-title":"Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array.","volume":"53","author":"Singh","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/J.CLINBIOCHEM.2004.03.006","article-title":"Historical prospective of human cytogenetics: from microscope to microarray.","volume":"37","author":"Smeets","year":"2004","journal-title":"Clin Biochem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"B2","DOI":"10.1016\/J.AJOG.2016.07.016","article-title":"The use of chromosomal microarray for prenatal diagnosis.","volume":"215","author":"Dugoff","year":"2016","journal-title":"Am J Obstet Gynecol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/09273972.2012.680234","article-title":"Ocular abnormalities and systemic disease in Down syndrome.","volume":"20","author":"Stirn Kranjc","year":"2012","journal-title":"Strabismus."},{"key":"B58","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/00006324-199710000-00023","article-title":"Refractive errors in young children with Down syndrome.","volume":"74","author":"Margaret Woodhouse","year":"1997","journal-title":"Optom Vis Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0161-6420(90)32399-0","article-title":"Nystagmus in Down\u2019s syndrome.","volume":"97","author":"Wagner","year":"1990","journal-title":"Ophthalmology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/JMG.2003.017731","article-title":"Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability\/mental retardation and dysmorphic features.","volume":"41","author":"Shaw-Smith","year":"2004","journal-title":"J Med Genet."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/EJHG.2016.73","article-title":"Clinical utility gene card for: Aniridia.","volume":"24","author":"Richardson","year":"2016","journal-title":"Eur J Hum Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/MOLEHR\/7.10.1001","article-title":"Clinical application of multiplex quantitative fluorescent polymerase chain reaction (QF-PCR) for the rapid prenatal detection of common chromosome aneuploidies.","volume":"7","author":"Cirigliano","year":"2001","journal-title":"Mol Hum Reprod."},{"key":"B63","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1038\/NG2092","article-title":"Copy number variations and clinical cytogenetic diagnosis of constitutional disorders.","volume":"39","author":"Lee","year":"2007","journal-title":"Nat Genet."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GNF056","article-title":"Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.","volume":"30","author":"Schouten","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"B65","article-title":"Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders.","volume":"14","author":"Redeker","year":"2008","journal-title":"Mol Vis."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/S12920-021-01034-6","article-title":"Retinoblastoma genetics screening and clinical management.","volume":"14","author":"Gupta","year":"2021","journal-title":"BMC Med Genom."},{"key":"B67","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/ICU.0000000000000185","article-title":"The current status of molecular diagnosis of inherited retinal dystrophies.","volume":"26","author":"Chiang","year":"2015","journal-title":"Curr Opin Ophthalmol."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/S00439-013-1381-5","article-title":"Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements.","volume":"133","author":"Wang","year":"2014","journal-title":"Hum Genet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/J.OPHTHA.2012.05.047","article-title":"Recommendations for genetic testing of inherited eye diseases: report of the American academy of ophthalmology task force on genetic testing.","volume":"119","author":"Stone","year":"2012","journal-title":"Ophthalmology."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2196\/23523","article-title":"Barriers and facilitators to genetic service delivery models: scoping review.","volume":"10","author":"Raspa","year":"2021","journal-title":"Interact J Med Res."},{"key":"B71","year":"2022"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/J.OPHTHA.2017.05.026","article-title":"The current state of teleophthalmology in the United States.","volume":"124","author":"Rathi","year":"2017","journal-title":"Ophthalmology."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-021-01756-X","article-title":"The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement.","volume":"16","author":"Black","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B74","author":"Testing","year":"2022","journal-title":"Help Me Understand Genetics."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-021-02145-0\/TABLES\/2","article-title":"Genetic testing and diagnosis of inherited retinal diseases.","volume":"16","author":"Lam","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/GIM.2015.15","article-title":"Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.","volume":"17","author":"Lee","year":"2015","journal-title":"Genet Med."},{"key":"B77","year":"2022","journal-title":"Genetic Testing For Retinal Degenerative Diseases: Information and Resources for Affected Individuals, Families and Health Care Providers."},{"key":"B78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/ARCHOPHT.125.2.196","article-title":"Molecular diagnosis and genetic counseling in ophthalmology.","volume":"125","author":"Blain","year":"2007","journal-title":"Arch Ophthalmol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/MGG3.1081","article-title":"Prevalence of mutations in inherited retinal diseases: a comparison between the United States and India.","volume":"8","author":"Yohe","year":"2020","journal-title":"Mol Genet genomic Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/S41586-019-1793-Z","article-title":"The genomeAsia 100K project enables genetic discoveries across Asia.","volume":"576","author":"Wall","year":"2019","journal-title":"Nature."},{"key":"B81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/GIM.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3980\/J.ISSN.2222-3959.2015.03.33","article-title":"Development of gene and stem cell therapy for ocular neurodegeneration.","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Ophthalmol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/D41573-018-00016-1","article-title":"Gene therapies in ophthalmic disease.","volume":"18","author":"Gordon","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9040882","article-title":"Large animal models of inherited retinal degenerations: a review.","volume":"9","author":"Winkler","year":"2020","journal-title":"Cells."},{"key":"B85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/J.PRETEYERES.2018.08.003","article-title":"Gene therapy for visual loss: opportunities and concerns.","volume":"68","author":"Lee","year":"2019","journal-title":"Prog Retin Eye Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: progress and possibilities.","volume":"104","author":"Hu","year":"2021","journal-title":"Clin Exp Optom."},{"key":"B87","author":"Kohl","year":"2018","journal-title":"Achromatopsia. GeneReviews\u00a7"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/HMG\/DDQ136","article-title":"Gene therapy rescues cone function in congenital achromatopsia.","volume":"19","author":"Kom\u00e1romy","year":"2010","journal-title":"Hum Mol Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1089\/HUM.2018.076","article-title":"Six years and counting: restoration of photopic retinal function and visual behavior following gene augmentation therapy in a sheep model of CNGA3 achromatopsia.","volume":"29","author":"Ofri","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/MT.2010.149","article-title":"Restoration of cone vision in the CNGA3-\/- mouse model of congenital complete lack of cone photoreceptor function.","volume":"18","author":"Michalakis","year":"2010","journal-title":"Mol Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/HUM.2015.142","article-title":"Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: Dose-dependent expression and improved retinal structure and function.","volume":"27","author":"Bush","year":"2016","journal-title":"Hum Gene Ther."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS13020219","article-title":"Viral-vector-delivered anti-angiogenic therapies to the eye.","volume":"13","author":"Koponen","year":"2021","journal-title":"Pharmaceutics."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAOPHTHALMOL.2018.6902","article-title":"Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial.","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.PRETEYERES.2018.03.003","article-title":"CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.","volume":"65","author":"Burnight","year":"2018","journal-title":"Prog Retin Eye Res."},{"key":"B95","year":"2022","journal-title":"Single Ascending Dose Study in Participants With LCA10 - Full Text View."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/D41586-020-00655-8","article-title":"CRISPR treatment inserted directly into the body for first time.","volume":"579","author":"Ledford","year":"2020","journal-title":"Nature."},{"key":"B97","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/S41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat Med."},{"key":"B98","year":"2022","journal-title":"Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1\/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10."},{"key":"B99","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/ANNUREV-NEURO-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases.","volume":"42","author":"Bennett Frank","year":"2019","journal-title":"Annu Rev Neurosci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/S00439-003-0970-0","article-title":"Novel types of mutation in the choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon.","volume":"113","author":"Van Den Hurk","year":"2003","journal-title":"Hum Genet."},{"key":"B101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-75402-4_11","article-title":"Antisense oligonucleotide-based splice correction of a deep-intronic mutation in CHM underlying choroideremia.","volume":"1074","author":"Garanto","year":"2018","journal-title":"Adv Exp Med Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/AOS.13273","article-title":"The intronic ABCA4 c.5461-10T>C variant, frequently seen in patients with Stargardt disease, causes splice defects and reduced ABCA4 protein level.","volume":"95","author":"Aukrust","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/S41436-018-0414-9","article-title":"Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides.","volume":"21","author":"Sangermano","year":"2019","journal-title":"Genet Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/S41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect.","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.EXER.2014.02.018","article-title":"The effect of the common c.2299delG mutation in USH2A on RNA splicing.","volume":"122","author":"Lenassi","year":"2014","journal-title":"Exp Eye Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/NAT.2014.0489","article-title":"Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection.","volume":"24","author":"Solano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"E517","DOI":"10.1073\/PNAS.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMOA0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis.","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMOA1412965\/SUPPL_FILE\/NEJMOA1412965_DISCLOSURES.PDF","article-title":"Improvement and decline in vision with gene therapy in childhood blindness.","volume":"372","author":"Jacobson","year":"2015","journal-title":"N Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000328206","article-title":"Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue.","volume":"226","author":"Lo","year":"2011","journal-title":"Ophthalmologica."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1167\/IOVS.14-13867","article-title":"Light damage in Abca4 and Rpe65rd12 Mice.","volume":"55","author":"Wu","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.EXER.2014.04.003","article-title":"All-trans-retinal induces Bax activation via DNA damage to mediate retinal cell apoptosis.","volume":"123","author":"Sawada","year":"2014","journal-title":"Exp Eye Res."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0006616","article-title":"Bax-induced apoptosis in Leber\u2019s congenital amaurosis: a dual role in rod and cone degeneration.","volume":"4","author":"Hamann","year":"2009","journal-title":"PLoS One."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2019.100827","article-title":"Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives.","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog Retin Eye Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1152\/PHYSIOLOGYONLINE.2000.15.3.120","article-title":"Apoptosis in the retina: the silent death of vision.","volume":"15","author":"Rem\u00e9","year":"2000","journal-title":"News Physiol Sci."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/CDDIS.2015.385","article-title":"Necrotic cone photoreceptor cell death in retinitis pigmentosa.","volume":"6","author":"Murakami","year":"2015","journal-title":"Cell Death Dis."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A008656","article-title":"Caspase functions in cell death and disease.","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/B978-0-12-801430-1.00002-0","article-title":"IAP family of cell death and signaling regulators.","volume":"545","author":"Silke","year":"2014","journal-title":"Methods Enzymol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/1535370213497320","article-title":"Inhibition of apoptosis by knockdown of caspase-3 with siRNA in rat bone marrow mesenchymal stem cells.","volume":"238","author":"Hua","year":"2013","journal-title":"Exp Biol Med (Maywood)."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2008.03.001","article-title":"Molecular chaperones and photoreceptor function.","volume":"27","author":"Kosmaoglou","year":"2008","journal-title":"Prog Retin Eye Res."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS17091584","article-title":"Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration.","volume":"17","author":"Kimura","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/J.VISRES.2004.12.020","article-title":"Effect of exogenous administration of nerve growth factorin the retina of rats with inherited retinitis pigmentosa.","volume":"45","author":"Lenzi","year":"2005","journal-title":"Vision Res."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/NCB0511-497","article-title":"Harnessing the potential of induced pluripotent stem cells for regenerative medicine.","volume":"13","author":"Wu","year":"2011","journal-title":"Nat Cell Biol."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0110324","article-title":"Neurotrophic requirements of human motor neurons defined using amplified and purified stem cell-derived cultures.","volume":"9","author":"Lamas","year":"2014","journal-title":"PLoS One."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/J.CELREP.2013.06.021","article-title":"Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes.","volume":"4","author":"Roybon","year":"2013","journal-title":"Cell Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(02)00835-8","article-title":"Directed differentiation of embryonic stem cells into motor neurons.","volume":"110","author":"Wichterle","year":"2002","journal-title":"Cell."},{"key":"B127","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00055735-200304000-00006","article-title":"Collaborative normal tension glaucoma study.","volume":"14","author":"Anderson","year":"2003","journal-title":"Curr Opin Ophthalmol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/BJO.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020.","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/J.EXER.2010.05.016","article-title":"Neurotrophic factor delivery as a protective treatment for glaucoma.","volume":"93","author":"Johnson","year":"2011","journal-title":"Exp Eye Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/S00441-013-1585-Y","article-title":"Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives.","volume":"353","author":"Unsicker","year":"2013","journal-title":"Cell Tissue Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000434703","article-title":"Neuroprotection and retinal diseases.","volume":"55","author":"Paulus","year":"2016","journal-title":"Dev Ophthalmol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/J.PRETEYERES.2018.02.002","article-title":"Neuroprotective strategies for retinal disease.","volume":"65","author":"Pardue","year":"2018","journal-title":"Prog Retin Eye Res."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-018-1041-8","article-title":"Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor\/tropomyosin-related kinase receptor-B signaling.","volume":"9","author":"Osborne","year":"2018","journal-title":"Cell Death Dis."},{"key":"B134","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/ICU.0000000000000140","article-title":"Optogenetics.","volume":"26","author":"Duebel","year":"2015","journal-title":"Curr Opin Ophthalmol."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2020.570909\/BIBTEX","article-title":"Optogenetic gene therapy for the degenerate retina: recent advances.","volume":"14","author":"McClements","year":"2020","journal-title":"Front Neurosci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy.","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat Med."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1189099\/v1","article-title":"Reactivating the phototransduction cascade by universally applicable gene therapy preserves retinal function in Rod-Cone dystrophy.","author":"Simon","year":"2021","journal-title":"Res Sq."},{"key":"B138","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.EXER.2018.09.003","article-title":"Optogenetic approaches to vision restoration.","volume":"178","author":"Simunovic","year":"2019","journal-title":"Exp Eye Res."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/10443.5394","article-title":"Non viral vectors in gene therapy- an overview.","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J Clin Diagn Res."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20225722","article-title":"Gene therapy in retinal dystrophies.","volume":"20","author":"Ziccardi","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2018.03.021","article-title":"Gene therapy for retinal degeneration.","volume":"173","author":"Apte","year":"2018","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/J.VISRES.2007.07.027","article-title":"Versatility of AAV vectors for retinal gene transfer.","volume":"48","author":"Surace","year":"2008","journal-title":"Vision Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.COVIRO.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors.","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr Opin Virol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14712598.2018.1484448","article-title":"Choroideremia: molecular mechanisms and development of AAV gene therapy.","volume":"18","author":"Patr\u00edcio","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/HMG\/10.26.3075","article-title":"Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model.","volume":"10","author":"Auricchio","year":"2001","journal-title":"Hum Mol Genet."},{"key":"B146","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J Virol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"7651","DOI":"10.1128\/JVI.76.15.7651-7660.2002","article-title":"Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size.","volume":"76","author":"Yang","year":"2002","journal-title":"J Virol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/JGM.1126","article-title":"Novel AAV serotypes for improved ocular gene transfer.","volume":"10","author":"Lebherz","year":"2008","journal-title":"J Gene Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/MT.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina.","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol Ther."},{"key":"B150","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/MT.2008.269","article-title":"High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.","volume":"17","author":"Petrs-Silva","year":"2009","journal-title":"Mol Ther."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/GT.2013.64","article-title":"Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.","volume":"21","author":"Mowat","year":"2014","journal-title":"Gene Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-62703-080-9_25","article-title":"Adeno-associated viral vectors for gene therapy of inherited retinal degenerations.","volume":"935","author":"Flannery","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/EMMM.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors.","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/GT.2014.8","article-title":"Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors.","volume":"21","author":"Colella","year":"2014","journal-title":"Gene Ther."},{"key":"B155","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/SJ.MT.6300081","article-title":"Efficient whole-body transduction with trans-splicing adeno-associated viral vectors.","volume":"15","author":"Ghosh","year":"2007","journal-title":"Mol Ther."},{"key":"B156","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/SJ.MT.6300322","article-title":"A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner.","volume":"16","author":"Ghosh","year":"2008","journal-title":"Mol Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/MT.2008.207","article-title":"A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs.","volume":"16","author":"Yue","year":"2008","journal-title":"Mol Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/GT.2013.3","article-title":"Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus.","volume":"20","author":"Lopes","year":"2013","journal-title":"Gene Ther."},{"key":"B159","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-4939-7522-8_11","article-title":"Dual AAV Vectors for Stargardt Disease.","volume":"1715","author":"Trapani","year":"2018","journal-title":"Methods Mol Biol."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMTHE.2017.11.019","article-title":"Triple vectors expand AAV transfer capacity in the retina.","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol Ther."},{"key":"B161","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.PRETEYERES.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies.","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog Retin Eye Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/J.DRUDIS.2019.05.038","article-title":"Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives.","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discov Today."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19092830","article-title":"Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application.","volume":"19","author":"Tsai","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B164","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/MED.21509","article-title":"Gold nanoparticles in ophthalmology.","volume":"39","author":"Masse","year":"2019","journal-title":"Med Res Rev."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/JFB6020379","article-title":"Lipid nanoparticles for ocular gene delivery.","volume":"6","author":"Wang","year":"2015","journal-title":"J Funct Biomater."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery.","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expert Opin Drug Deliv."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/J.MSEC.2017.04.068","article-title":"Non-viral strategies for ocular gene delivery.","volume":"77","author":"Oliveira","year":"2017","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCONREL.2015.10.007","article-title":"Non-viral therapeutic approaches to ocular diseases: an overview and future directions.","volume":"219","author":"Zulliger","year":"2015","journal-title":"J Contr Rel."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPB.2014.12.028","article-title":"Nanoparticle-based technologies for retinal gene therapy.","volume":"95","author":"Adijanto","year":"2015","journal-title":"Eur J Pharm Biopharm."},{"key":"B170","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/SJ.MT.6300365\/ATTACHMENT\/AF9198EF-D1E6-4BC6-89E9-D72BE35CC5F9\/MMC4.DOC","article-title":"Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA.","volume":"16","author":"Chen","year":"2008","journal-title":"Mol Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/HMG\/DDT013","article-title":"\/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA.","volume":"22","author":"Koirala","year":"2013","journal-title":"Hum Mol Genet."},{"key":"B172","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2217\/NNM.11.158","article-title":"Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity.","volume":"7","author":"Han","year":"2012","journal-title":"Nanomedicine (Lond)."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S157000","article-title":"DNA nanoparticles are safe and nontoxic in non-human primate eyes.","volume":"13","author":"Akelley","year":"2018","journal-title":"Int J Nanomed."},{"key":"B174","article-title":"Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina.","volume":"13","author":"Andrieu-Soler","year":"2007","journal-title":"Mol Vis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/J.EXER.2008.04.009","article-title":"Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration.","volume":"87","author":"Souied","year":"2008","journal-title":"Exp Eye Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/J.NANO.2011.01.006","article-title":"Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea.","volume":"7","author":"Sharma","year":"2011","journal-title":"Nanomedicine."},{"key":"B177","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1021\/ACS.MOLPHARMACEUT.8B00207","article-title":"Current progress in electrotransfection as a nonviral method for gene delivery.","volume":"15","author":"Cervia","year":"2018","journal-title":"Mol Pharm."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2217\/NNM-2016-0144","article-title":"Efficient and safe gene delivery to human corneal endothelium using magnetic nanoparticles.","volume":"11","author":"Czugala","year":"2016","journal-title":"Nanomedicine (Lond)."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1117\/1.JBO.22.6.060504","article-title":"Ultrafast laser-assisted spatially targeted optoporation into cortical axons and retinal cells in the eye.","volume":"22","author":"Batabyal","year":"2017","journal-title":"J Biomed Opt."},{"key":"B180","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.3892\/MMR.2015.4054\/HTML","article-title":"Gene therapy for ocular diseases meditated by ultrasound and microbubbles (Review).","volume":"12","author":"Wan","year":"2015","journal-title":"Mol Med Rep."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.2174\/1566523216666160331130040","article-title":"Gene electrotransfer: a mechanistic perspective.","volume":"16","author":"Rosazza","year":"2016","journal-title":"Curr Gene Ther."},{"key":"B182","article-title":"Technical brief: subretinal injection and electroporation into adult mouse eyes.","volume":"14","author":"Johnson","year":"2008","journal-title":"Mol Vis."},{"key":"B183","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1167\/IOVS.06-0092","article-title":"Gene transfer to rabbit retina with electron avalanche transfection.","volume":"47","author":"Chalberg","year":"2006","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2235688100","article-title":"From the Cover: INAUGURAL ARTICLE by a recently elected academy member:electroporation and RNA interference in the rodent retina in vivo and in vitro.","volume":"101","author":"Matsuda","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/MT.2011.304","article-title":"Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina.","volume":"20","author":"Touchard","year":"2012","journal-title":"Mol Ther."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0968-4328(01)00002-6","article-title":"Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach.","volume":"33","author":"Dezawa","year":"2002","journal-title":"Micron."},{"key":"B187","year":"2018","journal-title":"CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE."},{"key":"B188","year":"2022","journal-title":"Technology."},{"key":"B189","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(85)80025-8","article-title":"A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.","volume":"41","author":"Boshart","year":"1985","journal-title":"Cell."},{"key":"B190","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector.","volume":"108","author":"Hitoshi","year":"1991","journal-title":"Gene."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/NAR\/24.9.1787","article-title":"The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice.","volume":"24","author":"Schorpp","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/SCIENCE.1067081","article-title":"Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors.","volume":"295","author":"Lois","year":"2002","journal-title":"Science."},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/S11248-014-9857-1","article-title":"The newt (Cynops pyrrhogaster) RPE65 promoter: molecular cloning, characterization and functional analysis.","volume":"24","author":"Casco-Robles","year":"2015","journal-title":"Transgenic Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1076\/CEYR.24.5.368.8523","article-title":"Expression and promoter activation of the Rpe65 gene in retinal pigment epithelium cell lines.","volume":"24","author":"Boulanger","year":"2002","journal-title":"Curr Eye Res."},{"key":"B195","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/HUM.2015.130","article-title":"Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases.","volume":"27","author":"Ye","year":"2016","journal-title":"Hum Gene Ther."},{"key":"B196","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/PNAS.1821000116\/-\/DCSUPPLEMENTAL","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity.","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1089\/HUM.2012.125","article-title":"The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.","volume":"23","author":"Boye","year":"2012","journal-title":"Hum Gene Ther."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-6-13","article-title":"Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice.","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet Vaccines Ther."},{"key":"B199","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/J.OMTM.2020.03.003\/ATTACHMENT\/9230B41B-EF75-4F65-B3E9-5A4ABC22393E\/MMC1.PDF","article-title":"Empowering retinal gene therapy with a specific promoter for human rod and cone on-bipolar cells.","volume":"17","author":"Hulliger","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19082196","article-title":"Expanding the mutation spectrum in ABCA4: sixty novel disease causing variants and their associated phenotype in a large french Stargardt cohort.","volume":"19","author":"Nassisi","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2020.100861","article-title":"Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations.","volume":"79","author":"Cremers","year":"2020","journal-title":"Prog Retin Eye Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1034\/J.1399-0004.2003.00109.X","article-title":"The molecular genetics of Usher syndrome.","volume":"63","author":"Ahmed","year":"2003","journal-title":"Clin Genet."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/EJHG.2014.283","article-title":"A detailed clinical and molecular survey of subjects with nonsyndromic USH2A retinopathy reveals an allelic hierarchy of disease-causing variants.","volume":"23","author":"Lenassi","year":"2015","journal-title":"Eur J Hum Genet."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1136\/BJOPHTHALMOL-2020-315878","article-title":"Prevalence and genetic\u2013phenotypic characteristics of patients with USH2A mutations in a large cohort of Chinese patients with inherited retinal disease.","volume":"105","author":"Gao","year":"2021","journal-title":"Br J Ophthalmol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/NG1097-139","article-title":"Mutations in RPE65 cause Leber\u2019s congenital amaurosis.","volume":"17","author":"Marlhens","year":"1997","journal-title":"Nat Genet."},{"key":"B206","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/HUMC.2015.29004.SCH","article-title":"Investor outlook: significance of the positive LCA2 gene therapy phase III results.","volume":"26","author":"Schimmer","year":"2015","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/J.YMTHE.2017.03.008","article-title":"Taking stock of retinal gene therapy: looking back and moving forward.","volume":"25","author":"Bennett","year":"2017","journal-title":"Mol Ther."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/GT.2008.117","article-title":"Success in sight: the eyes have it! Ocular gene therapy trials for LCA look promising.","volume":"15","author":"Bainbridge","year":"2008","journal-title":"Gene Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/343364A0","article-title":"A point mutation of the rhodopsin gene in one form of retinitis pigmentosa.","volume":"343","author":"Dryja","year":"1990","journal-title":"Nature."},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A017129","article-title":"Genes and mutations causing autosomal dominant retinitis pigmentosa.","volume":"5","author":"Daiger","year":"2014","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B211","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/J.MITO.2018.07.006","article-title":"Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.","volume":"46","author":"Ham","year":"2019","journal-title":"Mitochondrion."},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/S41431-018-0235-Y","article-title":"Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches.","volume":"27","author":"Jurkute","year":"2019","journal-title":"Eur J Hum Genet."},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3390\/GENES10121050","article-title":"The spectrum of PAX6 mutations and genotype-phenotype correlations in the eye.","volume":"10","author":"Cunha","year":"2019","journal-title":"Genes (Basel)."},{"key":"B214","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/GT.2011.172","article-title":"Gene-based therapies for dominantly inherited retinopathies.","volume":"19","author":"Farrar","year":"2012","journal-title":"Gene Ther."},{"key":"B215","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/HMG\/DDX438","article-title":"Cas9\/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery.","volume":"27","author":"Giannelli","year":"2018","journal-title":"Hum Mol Genet."},{"key":"B216","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1167\/IOVS.09-4766","article-title":"Spectrum of rhodopsin mutations in french autosomal dominant rod\u2013cone dystrophy patients.","volume":"51","author":"Audo","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A017400","article-title":"Gene augmentation for adRP mutations in RHO.","volume":"4","author":"Lewin","year":"2014","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/CRISPR.2017.0009","article-title":"Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa.","volume":"1","author":"Li","year":"2018","journal-title":"Cris J."},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20061518","article-title":"X-linked retinitis pigmentosa in japan: clinical and genetic findings in male patients and female carriers.","volume":"20","author":"Kurata","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1177\/2515841418817490","article-title":"Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments.","volume":"10","author":"Mitsios","year":"2018","journal-title":"Ther Adv Ophthalmol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/ARCHOPHT.125.2.151","article-title":"Perspective on genes and mutations causing retinitis pigmentosa.","volume":"125","author":"Daiger","year":"2007","journal-title":"Arch Ophthalmol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1167\/IOVS.04-1482","article-title":"Identification of novel RPGR ORF15 mutations in x-linked progressive cone-rod dystrophy (XLCORD) families.","volume":"46","author":"Ebenezer","year":"2005","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B223","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/NG1321","article-title":"Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR.","volume":"36","author":"Ng","year":"2004","journal-title":"Nat Genet."},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAOPHTHALMOL.2018.3140","article-title":"Retinal angiography findings in male infant with incontinentia pigmenti and sickle cell trait.","volume":"136","author":"Moosajee","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMOA0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis.","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial.","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet (London, England)."},{"key":"B227","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.PRETEYERES.2014.09.001","article-title":"Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms.","volume":"45","author":"Zeitz","year":"2015","journal-title":"Prog Retin Eye Res."},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3390\/GENES9040215","article-title":"Special issue introduction: inherited retinal disease: novel candidate genes, genotype-phenotype correlations, and inheritance models.","volume":"9","author":"Cremers","year":"2018","journal-title":"Genes (Basel)."},{"key":"B229","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/IIO.0000000000000364","article-title":"Gene therapies for the treatment of leber hereditary optic neuropathy.","volume":"61","author":"Sahel","year":"2021","journal-title":"Int Ophthalmol Clin."},{"key":"B230","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/ANNUREV-NEURO-062012-170304","article-title":"Gene therapy for blindness.","volume":"36","author":"Sahel","year":"2013","journal-title":"Annu Rev Neurosci."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/S00417-013-2314-7","article-title":"Functional rescue of cone photoreceptors in retinitis pigmentosa.","volume":"251","author":"Sahel","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/J.BBRC.2019.12.117","article-title":"Opsins for vision restoration.","volume":"527","author":"Simon","year":"2020","journal-title":"Biochem Biophys Res Commun."},{"key":"B233","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/J.PRETEYERES.2018.10.001","article-title":"The clinical relevance of visualising the peripheral retina.","volume":"68","author":"Quinn","year":"2019","journal-title":"Prog Retin Eye Res."},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/634351","article-title":"Multimodal imaging in hereditary retinal diseases.","volume":"2013","author":"Pichi","year":"2013","journal-title":"J Ophthalmol."},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2020.100898","article-title":"The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies.","volume":"82","author":"De Silva","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial.","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet."},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1167\/IOVS.11-8554","article-title":"Transition zones between healthy and diseased retina in choroideremia (CHM) and stargardt disease (STGD) as compared to retinitis pigmentosa (RP).","volume":"52","author":"Lazow","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B238","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/GIM.2014.138","article-title":"Genotype-phenotype correlation and mutation spectrum in a large cohort of patients with inherited retinal dystrophy revealed by next-generation sequencing.","volume":"17","author":"Huang","year":"2015","journal-title":"Genet Med."},{"key":"B239","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/ARCHOPHTHALMOL.2010.309","article-title":"Genotype-phenotype correlation for leber congenital amaurosis in Northern Pakistan.","volume":"128","author":"McKibbin","year":"2010","journal-title":"Arch Ophthalmol."},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1038\/srep44465","article-title":"Analysis of RP2 and RPGR mutations in five X-linked chinese families with retinitis pigmentosa.","volume":"7","author":"Jiang","year":"2017","journal-title":"Sci Rep."},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1186\/S12886-020-01791-5","article-title":"X-linked dominant RPGR gene mutation in a familial Coats angiomatosis.","volume":"21","author":"Nebbioso","year":"2021","journal-title":"BMC Ophthalmol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1167\/IOVS.12-11541","article-title":"Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa.","volume":"54","author":"Churchill","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B243","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/EYE.2008.427","article-title":"Phenotypic progression in X-linked retinitis pigmentosa secondary to a novel mutation in the RPGR gene.","volume":"23","author":"Al-Maskari","year":"2009","journal-title":"Eye (Lond)."},{"key":"B244","article-title":"Variable phenotypic expressivity in a Swiss family with autosomal dominant retinitis pigmentosa due to a T494M mutation in the PRPF3 gene.","volume":"16","author":"Vaclavik","year":"2010","journal-title":"Mol Vis."},{"key":"B245","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/J.STEMCR.2016.12.008","article-title":"iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice.","volume":"8","author":"Mandai","year":"2017","journal-title":"Stem Cell Rep."},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/J.MCN.2020.103523","article-title":"Human pluripotent stem cells: a toolbox to understand and treat retinal degeneration.","volume":"107","author":"Morizur","year":"2020","journal-title":"Mol Cell Neurosci."},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02955-3","article-title":"Stem\/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials.","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS11071120","article-title":"Brain and retinal organoids for disease modeling: the importance of in vitro blood-brain and retinal barriers studies.","volume":"11","author":"Martinelli","year":"2022","journal-title":"Cells."},{"key":"B249","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0140-6736(12)60028-2","article-title":"Embryonic stem cell trials for macular degeneration: a preliminary report.","volume":"379","author":"Schwartz","year":"2012","journal-title":"Lancet (London, England)."},{"key":"B250","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies.","volume":"385","author":"Schwartz","year":"2015","journal-title":"Lancet (London, England)."},{"key":"B251","doi-asserted-by":"publisher","first-page":"ORSFc1","DOI":"10.1167\/IOVS.15-18681","article-title":"Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years.","volume":"57","author":"Schwartz","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B252","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/J.STEMCR.2015.04.005","article-title":"Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients.","volume":"4","author":"Song","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B253","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/NBT0915-890","article-title":"RIKEN suspends first clinical trial involving induced pluripotent stem cells.","volume":"33","author":"Garber","year":"2015","journal-title":"Nat Biotechnol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/357455A0","article-title":"Human gene therapy comes of age.","volume":"357","author":"Miller","year":"1992","journal-title":"Nature"},{"key":"B255","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration.","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet (London, England)."},{"key":"B256","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/00006982-200512001-00045","article-title":"The food and drug administration\u2019s office of orphan products development: incentives, grants, and special designations speed therapies for orphan diseases.","volume":"25","author":"Haffner","year":"2005","journal-title":"Retina."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T04:42:38Z","timestamp":1657860158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":256,"alternative-id":["10.3389\/fmed.2022.906482"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.906482","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"article-number":"906482"}}